Food and Drug Department, University of Parma , 43124 Parma, Italy.
Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, R+DPharma Group (GI-1645), Facultad de Farmacia and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela , 15872 Santiago de Compostela, Spain.
Mol Pharm. 2018 Feb 5;15(2):571-584. doi: 10.1021/acs.molpharmaceut.7b00939. Epub 2018 Jan 24.
Cyclosporine is an immunosuppressant agent approved for the treatment of dry eye disease and used off-label for other ocular pathologies. Its formulation and ocular bioavailability present a real challenge due to the large molecular weight (1.2 kDa), high lipophilicity, and low water solubility. The aim of the work was to develop an aqueous micellar formulation for an efficient cyclosporine delivery to the ocular tissues, using a water-soluble derivative of vitamin E (TPGS: d-α-tocopheryl polyethylene glycol 1000 succinate) and poloxamer 407 (Pluronic ®F127) as excipients. The mixed micelles were characterized in terms of particle size, zeta potential, rheology, and stability upon dilution and freeze-drying. Additionally, the enzymatic-triggered release of vitamin E and vitamin E succinate from TPGS was investigated in vitro in the presence of esterase. Compared to the commercially available ophthalmic formulation, the poloxamer 407:TPGS 1:1 molar ratio micellar formulation significantly improved cyclosporine solubility, which increased proportionally to surfactant concentration reaching 0.4% (w/v) for 20 mM surfactant total concentration. Cyclosporine-loaded mixed micelles efficiently retained the drug once diluted in simulated lachrymal fluid and, in the presence of a 20 mM surfactant concentration, were stable upon freeze-drying. The drug-loaded mixed micelles were applied ex vivo on porcine cornea and compared to Ikervis®. Drug accumulation in the cornea resulted proportional to drug concentration (6.4 ± 1.9, 17.6 ± 5.4, and 26.9 ± 7.4 μg/g, after 3 h for 1, 2.5, and 4 mg/mL cyclosporine concentration respectively). The formulation containing cyclosporine 4 mg/mL (20 mM surfactant) was also evaluated on the sclera, with a view to targeting the posterior segment. The results demonstrated the capability of mixed micelles to diffuse into the sclera and sustain cyclosporine delivery (28 ± 7, 38 ± 10, 57 ± 9, 145 ± 27 μg/cm cyclosporine accumulated after 3, 6, 24, and 48 h respectively). Reservoir effect experiments demonstrated that the drug accumulated in the sclera can be slowly released into the underlying tissues. Finally, all the formulations developed in this work successfully passed the HET-CAM assay for the evaluation of ocular irritability.
环孢素是一种免疫抑制剂,已被批准用于治疗干眼症,并被用于治疗其他眼部疾病。由于其分子量较大(1.2 kDa)、亲脂性高和水溶性低,其制剂和眼部生物利用度是一个真正的挑战。本工作的目的是开发一种用于眼部组织的环孢素高效递药的水胶态制剂,使用维生素 E 的水溶性衍生物(TPGS:d-α-生育酚聚乙二醇 1000 琥珀酸酯)和泊洛沙姆 407(Pluronic ®F127)作为辅料。混合胶束的粒径、Zeta 电位、流变学和稀释及冻干后的稳定性进行了表征。此外,还在酯酶存在的情况下,研究了 TPGS 中维生素 E 和维生素 E 琥珀酸酯的酶触发释放。与市售的眼用制剂相比,泊洛沙姆 407:TPGS 1:1 摩尔比胶束制剂显著提高了环孢素的溶解度,随着表面活性剂浓度的增加,环孢素溶解度呈比例增加,当表面活性剂总浓度达到 0.4%(w/v)时达到最大。环孢素载药混合胶束在模拟泪液中稀释后能有效地保留药物,并且在 20 mM 表面活性剂浓度下,冻干后稳定。载药混合胶束被应用于猪角膜的离体研究,并与 Ikervis ®进行了比较。药物在角膜中的蓄积量与药物浓度成正比(3 h 时,1、2.5 和 4 mg/mL 环孢素浓度分别为 6.4 ± 1.9、17.6 ± 5.4 和 26.9 ± 7.4 μg/g)。还评估了含有 4 mg/mL 环孢素(20 mM 表面活性剂)的制剂在巩膜上的应用,以期靶向后节。结果表明,混合胶束能够扩散到巩膜并持续递药(3、6、24 和 48 h 时分别为 28 ± 7、38 ± 10、57 ± 9、145 ± 27 μg/cm 环孢素累积)。储库效应实验表明,药物在巩膜中的蓄积可以缓慢释放到下面的组织中。最后,本工作开发的所有制剂均成功通过 HET-CAM 试验,用于评估眼部刺激性。